Cubist Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 92   

Articles published

CBST 68.20 0.00 (0.00%)
price chart
Cubist Pharmaceuticals' CEO Discusses Q1 2014 Results - Earnings Call ...
Good day. My name is Julie, and I'll be your event manager today. At this time, I would like to welcome everyone to the First Quarter 2014 Earnings Conference Call.
Cubist Pharmaceuticals Reports First Quarter 2014 Financial Results  Business Wire (press release)
Cubist Pharma Q1 Profit Surges  RTT News
Related articles »  
Cubist Pharmaceuticals Inc.: Cubist Pharmaceuticals Reports First Quarter 2014 ...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced results for the first quarter ended March 31, 2014.
What's Next for Cubist Pharmaceuticals Inc. and Durata Therapeutics, Inc.?
Cubist Pharmaceuticals (NASDAQ: CBST ) and Durata Therapeutics (NASDAQ: DRTX ) both won this week with nods by the FDA's advisory panels on each company's antibacterial agents. In two unanimous votes, the FDA panels agreed on the safety and ...
Related articles »  
Cubist Pharmaceuticals Issues Recall Due to Glass Particles in Vials
Cubist Pharmaceuticals, Inc. announced on April 18 that it is voluntarily recalling one lot of CUBICIN (daptomycin for injection) to the user level due to the presence of particulate matter, reported via customer complaint and identified as glass ...
Cubist Pharmaceuticals (CBST) Announces Quarterly Earnings, Misses ...
Cubist Pharmaceuticals logo Cubist Pharmaceuticals (NASDAQ:CBST) issued its quarterly earnings data on Tuesday. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by $0.03, ...
Cubist Pharmaceuticals Price Target Increased to $90.00 by Analysts at Leerink ...
Cubist Pharmaceuticals Inc logo Cubist Pharmaceuticals (NASDAQ:CBST) had its price target increased by Leerink Swann from $80.00 to $90.00 in a research report sent to investors on Monday morning, StockRatingsNetwork.
Cubist Pharmaceuticals Issues Voluntary Recall of Tainted Cubicin Lot
Cubist Pharmaceuticals Inc. (CBST) said Friday that it is voluntarily recalling a lot of Cubicin treatment after a customer reported finding glass particles in a vial.
Cubist Pharmaceuticals Issues Voluntary Nationwide Recall of One Lot of ...  Business Wire (press release)
Cubist Pharma Recalls One Lot Of Cubicin Due To Presence Of Particulate Matter  NASDAQ
Related articles »  
Cubist Pharmaceuticals issues voluntary nationwide recall of one lot of ...
Cubist Pharmaceuticals Inc.is voluntarily recalling one lot of Cubicin (daptomycin for injection) to the user level due to the presence of particulate matter, reported via customer complaint and identified as glass particles, found in a single vial ...
Cubist Pharmaceuticals (CBST) to Release Quarterly Earnings on Tuesday
Cubist Pharmaceuticals (NASDAQ:CBST) last announced its earnings results on Wednesday, January 22nd. The company reported $0.29 earnings per share for the quarter, beating the analysts' consensus estimate of ($0.01) by $0.30.
RSI Alert: Cubist Pharmaceuticals (CBST) Now Oversold
In trading on Monday, shares of Cubist Pharmaceuticals Cubist Pharmaceuticals Inc. (NASD: CBST) entered into oversold territory, hitting an RSI reading of 29.2, after changing hands as low as $65.76 per share.
Related articles »